MétaCan
Menu
Back to cohort
Record W2323840860 · doi:10.18632/oncotarget.7883

Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2

2016· article· en· W2323840860 on OpenAlexafffundabout
Mateusz Rytelewski, Saman Maleki Vareki, Lingegowda S. Mangala, Larissa Romanow, Dahai Jiang, Sunila Pradeep, Cristian Rodriguez‐Aguayo, Gabriel Lopez‐Berestein, René Figueredo, Peter J. Ferguson, Mark Vincent, Anil K. Sood, James Koropatnick

Bibliographic record

VenueOncotarget · 2016
Typearticle
Languageen
FieldMedicine
TopicPARP inhibition in cancer therapy
Canadian institutionsLawson Health Research InstituteWestern University
FundersNational Center for Advancing Translational SciencesNational Institutes of HealthNational Cancer InstituteCanadian Institutes of Health ResearchCancer Prevention and Research Institute of TexasRGK Foundation
KeywordsOlaparibCancer researchPARP inhibitorMedicineOvarian cancerPopulationPARP1OncologyCancerInternal medicineBiologyPoly ADP ribose polymeraseGenetics

Abstract

fetched live from OpenAlex

// Mateusz Rytelewski 1, 6 , Saman Maleki Vareki 6 , Lingegowda S. Mangala 3, 5 , Larissa Romanow 1 , Dahai Jiang 3, 4 , Sunila Pradeep 4 , Christian Rodriguez-Aguayo 3, 4 , Gabriel Lopez-Berestein 4, 5 , Rene Figueredo 2 , Peter J. Ferguson 6 , Mark Vincent 2, 6 , Anil K. Sood 3, 5, 7 , James D. Koropatnick 1, 2, 6 1 Department of Microbiology and Immunology, Western University, London, ON, Canada 2 Department of Oncology, Western University, London, ON, Canada 3 Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 4 Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 5 Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 6 Lawson Health Research Institute, London, ON, Canada 7 Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Correspondence to: James D. Koropatnick, e-mail: jkoropat@uwo.ca Keywords: DNA repair, resistance, BRCA2, PARP1, antisense Received: February 09, 2016     Accepted: February 17, 2016     Published: March 03, 2016 ABSTRACT Human tumor heterogeneity promotes therapeutic failure by increasing the likelihood of resistant cell subpopulations. The PARP-1 inhibitor olaparib is approved for use in BRCA-mutated ovarian cancers but BRCA2-reversion mutations lead to functional homologous recombination repair (HRR) and olaparib resistance. To overcome that resistance and expand use of PARP1 inhibition to cancers with functional HRR, we developed an antisense strategy to render the majority of tumor cells in a population BRCA2-deficient. We predicted that this strategy would render HRR-proficient tumor cells sensitive to olaparib and prevent emergence of resistance in a tumor cell population heterogeneous for HRR proficiency. We report that BRCA2 downregulation sensitized multiple human tumor cell lines (but not non-cancer human kidney cells) to olaparib and, combined with olaparib, increased aneuploidy and chromosomal translocations in human tumor cells. In a mixed HRR-proficient and HRR-deficient cell population, olaparib monotherapy allowed outgrowth of HRR-proficient cells resistant to subsequent olaparib treatment. Combined BRCA2 inhibition and olaparib treatment prevented selection of HRR-proficient cells and inhibited proliferation of the entire population. Treatment with BRCA2 siRNA and olaparib decreased ovarian xenograft growth in mice more effectively than either treatment alone. In vivo use of BRCA2 antisense oligonucleotides may be a viable option to expand clinical use of olaparib and prevent resistance.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.112
Threshold uncertainty score0.593

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.299
Teacher spread0.286 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations10
Published2016
Admission routes3
Has abstractyes

Explore more

Same venueOncotargetSame topicPARP inhibition in cancer therapyFrench-language works237,207